AbbVie Forecast, price target & analysts
AbbVie Target price 2026 - Analyst rating & recommendation
AbbVie Classifications & Recommendation
AbbVie Price Target
| Target Price | $287.64 |
| Price | $262.82 |
| Potential |
9.44%
register free of charge
|
| Number of Estimates | 33 |
|
33 Analysts have issued a price target AbbVie 2027 .
The average AbbVie target price is $287.64.
This is
9.44%
register free of charge
$344.40
31.04%
register free of charge
$199.02
24.28%
register free of charge
|
|
| A rating was issued by 39 analysts: 32 Analysts recommend AbbVie to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AbbVie stock has an average upside potential 2027 of
9.44%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 61.16 | 68.99 |
| 8.57% | 12.80% | |
| EBITDA Margin | 47.54% | 48.53% |
| 7.63% | 2.08% | |
| Net Margin | 6.84% | 36.63% |
| 9.02% | 435.19% |
35 Analysts have issued a sales forecast AbbVie 2026 . The average AbbVie sales estimate is
This results in the following potential growth metrics:
20 Analysts have issued an AbbVie EBITDA forecast 2026. The average AbbVie EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
36 AbbVie Analysts have issued a net profit forecast 2026. The average AbbVie net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.36 | 14.30 |
| 1.26% | 505.93% | |
| P/E | 18.38 | |
| EV/Sales | 7.66 |
36 Analysts have issued a AbbVie forecast for earnings per share. The average AbbVie EPS is
This results in the following potential growth metrics and future valuations:
Current AbbVie Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HSBC |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| BNP Paribas |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HSBC:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
BNP Paribas:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 04 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
